fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.
Company profile
Ticker
FENC
Exchange
Website
CEO
Rostislav Raykov
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADHEREX TECHNOLOGIES INC
SEC CIK
Corporate docs
Subsidiaries
Oxiquant, Inc. • Cadherin Biomedical Inc. • Fennec Pharmaceuticals (EU) Limited ...
FENC stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Mar 24
8-K
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
25 Mar 24
8-K
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
21 Mar 24
424B7
Prospectus with selling stockholder info
15 Mar 24
8-K/A
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
6 Mar 24
8-K
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
29 Feb 24
8-K
FDA Issues Reminder of Non-Substitution of PEDMARKÒ (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
2 Feb 24
EFFECT
Notice of effectiveness
18 Dec 23
CORRESP
Correspondence with SEC
13 Dec 23
8-K
Fennec Announces Incremental $5 Million Investment from Petrichor
5 Dec 23
Latest ownership filings
144
Notice of proposed sale of securities
17 Apr 24
4
Adrian Haigh
16 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
4
CHRIS A RALLIS
15 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Rosty Raykov
5 Apr 24
144
Notice of proposed sale of securities
5 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Rosty Raykov
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.40 mm | 12.40 mm | 12.40 mm | 12.40 mm | 12.40 mm | 12.40 mm |
Cash burn (monthly) | 853.00 k | 1.45 mm | 339.00 k | 1.42 mm | 920.00 k | 1.59 mm |
Cash used (since last report) | 5.64 mm | 9.57 mm | 2.24 mm | 9.42 mm | 6.09 mm | 10.52 mm |
Cash remaining | 6.75 mm | 2.83 mm | 10.16 mm | 2.98 mm | 6.31 mm | 1.88 mm |
Runway (months of cash) | 7.9 | 2.0 | 30.0 | 2.1 | 6.9 | 1.2 |
Institutional ownership, Q2 2023
66.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 57 |
Opened positions | 21 |
Closed positions | 17 |
Increased positions | 18 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 123.69 bn |
Total shares | 18.08 mm |
Total puts | 35.10 k |
Total calls | 112.10 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Southpoint Capital Advisors | 4.08 mm | $36.00 bn |
Essetifin SPA | 3.99 mm | $24.96 mm |
Sonic GP | 2.41 mm | $21.26 bn |
Solas Capital Management | 1.44 mm | $12.71 bn |
Avoro Capital Advisors | 1.20 mm | $10.60 bn |
DG Capital Management | 1.07 mm | $9.49 bn |
BLK Blackrock | 830.12 k | $7.33 bn |
Harbert Fund Advisors | 466.87 k | $4.12 bn |
AIGH Capital Management | 349.46 k | $3.09 bn |
683 Capital Management | 300.00 k | $2.65 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Apr 24 | Adrian Haigh | Common Shares | Sell | Dispose S | No | Yes | 10.2776 | 22,222 | 228.39 k | 0 |
16 Apr 24 | Adrian Haigh | Common Shares | Sell | Acquire S | No | Yes | 2.31 | 22,222 | 51.33 k | 44,444 |
16 Apr 24 | Adrian Haigh | Common Shares Options | Option exercise | Dispose M | No | Yes | 2.31 | 22,222 | 51.33 k | 449,135 |
15 Apr 24 | Rallis Chris A | Common Shares | Option exercise | Acquire M | No | Yes | 10.45 | 1,389 | 14.52 k | 45,838 |
15 Apr 24 | Rallis Chris A | Common Shares | Sell | Dispose S | No | No | 10.45 | 800 | 8.36 k | 44,449 |
15 Apr 24 | Rallis Chris A | Common Shares Options | Option exercise | Dispose M | No | Yes | 3.6 | 1,389 | 5.00 k | 181,594 |
15 Apr 24 | Adrian Haigh | Common Shares | Sell | Dispose S | No | Yes | 10.2958 | 22,222 | 228.79 k | 22,222 |
15 Apr 24 | Adrian Haigh | Common Shares | Sell | Acquire S | No | Yes | 2.31 | 22,222 | 51.33 k | 22,222 |
15 Apr 24 | Adrian Haigh | Common Shares Options | Option exercise | Dispose M | No | Yes | 2.31 | 22,222 | 51.33 k | 471,357 |
5 Apr 24 | Raykov Rosty | Common shares | Sell | Dispose S | No | Yes | 10.751 | 44,300 | 476.27 k | 187,471 |
News
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $18
4 Apr 24
Earnings Scheduled For March 21, 2024
21 Mar 24
Fennec Pharmaceuticals Q4 EPS $(0.10) Misses $(0.02) Estimate, Sales $9.73M Beat $8.67M Estimate
21 Mar 24
Fennec Pharmaceuticals's Earnings Outlook
20 Mar 24
Craig-Hallum Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $18
18 Mar 24
Press releases
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
17 Mar 24
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
29 Feb 24
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
1 Feb 24